Ji- Eon Won

Eli Lilly

Ji-Eon Won earned Masters in Medicine (Internal Medicine) from Hallym University School of Medicine, Korea and Fellowship Medicine (Internal Medicine) from Seoul National University Bundang Hospital, Korea.

She is the Medical Launch Leader for North Asia Pacific Hub Dermatology at Eli Lilly and Company. She has handled Ixekizumab and Baricitinib Asian projects. 

She held the following positions:
      -Senior Medical Advisor for Immunology at Lilly Korea.
      -Medical lead: KFDA approval of Ixekizumab in Psoriasis / Psoriatic arthritis
      -Medical lead: KFDA approval of baricitinib in rheumatoid arthritis
      -Medical reviewer: Ixekizumab PMS protocols in Psoriasis / Psoriatic arthritis 
                             Baricitinib PMS protocol in Rheumatoid arthritis

Ji-Eon has clinical trial experience in Immunology
        Clinical trials: RHBP, COAST-W, COAST-V, COAST-X, AMAK, AMAJ, JAHM, JAIY, JAHO



E-Posters by Ji- Eon Won
52-week safety profile of ixekizumab in Asian patients with moderate-to-severe plaque psoriasis: An integrated analysis from UNCOVER-1 and IXORA-P studies
52-week safety profile of ixekizumab in Asian patients with moderate-to-severe plaque psoriasis: An integrated analysis from UNCOVER-1 and IXORA-P studies
Tsen-Fang Tsai, Sang Woong Youn, Torii Hideshi, Lu Zhang, Martin Dossenbach, Chia-Fang Lee, Hitoe Torisu-Itakura, Ji-Eon Won